Financial Data and Key Metrics Changes - The company reported approximately $67.3 million in revenues for Q4 2025 and approximately $72.8 million for the full year 2025, compared to approximately $1.5 million and $27.9 million for the same periods in 2024, indicating significant growth [17][18] - Net profit for Q4 2025 was approximately $56.8 million or approximately $0.60 per share, compared to a net loss of approximately $6.1 million or approximately $0.07 per share in Q4 2024 [19] - For the full year 2025, net profit was approximately $35.3 million or approximately $0.38 per share, compared to a net loss of approximately $14.2 million or approximately $0.16 per share in 2024 [20] Business Line Data and Key Metrics Changes - The company advanced its clinical programs, initiating new trials for COM-701 and GS-0321, with significant updates presented at major conferences [5][10] - The MAIA-ovarian trial for COM-701 has expanded its footprint globally, with sites opened in the U.S., France, and Israel [9] Market Data and Key Metrics Changes - The partnership with AstraZeneca has been strengthened through a transaction that added $65 million in upfront non-dilutive capital, extending the cash runway into 2029 [6][16] - The company retains the majority of its royalty interest in rilvegostomig, which is projected to have a peak annual revenue potential of over $5 billion [8] Company Strategy and Development Direction - The company aims to continue executing its clinical trials, particularly the MAIA-ovarian trial, and is focused on advancing its early-stage pipeline [10][14] - The leadership transition to a new CEO is expected to provide operational focus and strategic continuity for the company's growth [4][8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the differentiation of their products and the strategic execution of clinical trials, particularly in the context of the competitive landscape [12][13] - The company is committed to leveraging its computational drug target discovery engine to deliver innovative immune oncology assets [14] Other Important Information - The company has a solid balance sheet with approximately $145.6 million in cash equivalents as of December 31, 2025, which will support its operational plans into 2029 [16] - The company is eligible for up to $758 million in future milestones and tiered royalties from its partnership with Gilead [11] Q&A Session Summary Question: What to expect in the 1Q 2027 update with COM-701? - Management indicated that the current trial is an adaptive design and anticipates data maturation in 1Q 2027, with the timeline for registration depending on the totality of the data [23][24] Question: Cadence of potential outlying milestones for rilvegostomig? - The next milestone is BLA acceptance, which will trigger an additional $25 million payment, with a total of $195 million in milestones remaining from AstraZeneca [27][28] Question: Reason for the shift in interim analysis timing for the ovarian trial? - The shift to Q1 2027 was due to slower opening of major academic sites, but all sites are now open and on track for the readout [32][34] Question: Discussions on expanding the use of COM-902 derived TIGIT? - Management noted that AstraZeneca is expanding rilvegostomig but did not discuss specific plans for COM-902 [35] Question: Data expectations for GS-0321? - Data reporting will align with Gilead's guidelines, typically presented at scientific conferences, including activity and safety [36]